Industrial Biotechnology Association
Executive Summary
Mycogen CEO Jerry Caulder elected chairman of the biotech trade group for 1989-90. He succeeds Schering-Plough Exec VP-Administration Hugh D'Andrade, who will remain on the association's board. Caulder identified some of the key industry issues as health care reimbursement, protection of intellectual property rights, the patent backlog and the release of genetically engineered organisms. Other officers elected to one-year terms are Vice Chairman Stephen Duzan, president, Immunex; Merck Senior VP Charles Leighton, secretary; Calgene CEO Roger Salquist, treasurer; and President Richard Godown. All but Godown also serve as IBA directors.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.